What are Mission Vision & Core Values of Shanghai Henlius Biotech Company?

The mission statement explicitly places patients at the center of Henlius Biotech's focus. The primary goal is to improve the lives of patients worldwide. This patient-centricity guides all aspects of the company's operations, from research and development to commercialization.

Henlius Biotech's commitment extends to providing 'quality and affordable protein therapeutics.' This encompasses both biosimilars and innovative biologics. The company aims to make these essential medicines accessible to a broad patient population, reflecting its commitment to corporate social responsibility.

The mission statement highlights a global market scope. Henlius Biotech aims to improve lives universally, not just in specific regions. This global ambition is reflected in its regulatory approvals and market presence across multiple countries, including China, Europe, and the United States.

The mission emphasizes 'technical innovation and operational excellence' as the means to achieve its goals. This highlights Henlius Biotech's focus on both the efficacy and accessibility of its therapies. These pillars drive the company's approach to research, development, and manufacturing.

The successful launch of products like HANQUYOU (trastuzumab biosimilar) in multiple regions exemplifies the mission in action. In 2024, Henlius reported that over 100,000 patients have been treated with HANQUYOU worldwide. The inclusion of products in reimbursement lists, such as HANQUYOU and HANSIZHUANG in China, further demonstrates the company's commitment to affordability and patient access.

Henlius Biotech's long-term vision, guided by its mission, is to become a leading biopharmaceutical company. This includes expanding its product portfolio, increasing its global presence, and continuously innovating to meet unmet medical needs. The company's strategic objectives are directly aligned with its mission.

The vision is highly aspirational, aiming for market leadership and recognition. It sets a high bar, challenging Henlius to consistently deliver on its promises of quality, innovation, and patient-centric care. This ambition is reflected in the company's strategic objectives and its commitment to advancing healthcare.

The vision's scope is global, aspiring to provide medicines 'for all patients'. This broad scope highlights Henlius's commitment to addressing unmet medical needs worldwide. This global reach is evident in its product approvals in over 50 countries and regions, demonstrating its ability to navigate diverse regulatory landscapes.

The vision is realistic, given Henlius's current trajectory and capabilities. However, achieving the status of "most trusted" in the competitive biopharmaceutical industry requires sustained excellence. This includes consistent quality, ethical practices, and positive patient outcomes, all of which are critical to the company's long-term success.

The vision emphasizes both innovation and affordability. Henlius aims to provide innovative medicines while also ensuring they are accessible to all patients. This dual focus is reflected in their development of both innovative biologics and affordable biosimilars. This approach is a key part of the company strategy.

Henlius's commitment to research and development is a critical enabler of its vision. The company's significant investment in R&D, reaching RMB 1.8405 billion in 2024, and its expanding pipeline of approximately 50 molecules, demonstrate its dedication to innovation. This investment is vital for achieving its long-term vision.

The vision underscores Henlius's potential impact on healthcare. By providing innovative and affordable medicines, the company aims to improve patient outcomes and address critical medical needs. This commitment to healthcare is a core aspect of its corporate values.

Driven by its mission and vision, Shanghai Henlius Biotech has adopted an aggressive global expansion strategy. The company aims to serve patients worldwide, leading to approvals and partnerships in numerous countries. This global reach is a direct reflection of its commitment to providing access to its medicines.

As of May 2025, Henlius has secured product approvals in over 50 countries and regions. This extensive global presence underscores the company's dedication to its vision of becoming a trusted global biopharma. The company's strategic focus on major markets like the U.S., EU, and Japan is a testament to its ambition.

Henlius Biotech strategically leverages partnerships to enhance its global reach and market penetration. Collaborations, such as the agreement with Sandoz for the commercialization of an ipilimumab biosimilar, demonstrate its strategy to increase patient access. These partnerships are crucial for achieving its mission and vision.

Henlius Biotech's substantial investment in research and development is a clear indication of its commitment to innovation. The company's financial success, with a net profit of RMB 820.5 million in 2024, demonstrates the effectiveness of its mission-driven strategy. This financial performance supports its future growth.

In 2024, Henlius Biotech's R&D expenditure reached RMB 1.8405 billion, marking a 28.4% year-on-year increase. This significant investment is crucial for developing the innovative and quality products central to its mission and vision. The continuous investment in R&D is a key driver of its strategic objectives.

Jason Zhu, Executive Director and CEO of Henlius, emphasizes the company's patient-centric approach and innovation-driven R&D. His statements highlight the importance of the mission and vision in guiding the company's strategic goals. This focus ensures that the company remains aligned with its core values.

Leadership plays a crucial role in reinforcing the Henlius mission vision and core values. CEO Jason Zhu's emphasis on a 'patient-centric philosophy' highlights the top-down commitment to their core purpose.

Communicating the Henlius mission vision to all stakeholders is vital for building trust and ensuring alignment. Henlius utilizes various platforms to communicate its progress and commitment to its goals.

Concrete examples of alignment between stated values and actual practices are evident in Henlius's operations. Quality control measures, such as GMP certifications, are a testament to their commitment to excellence.

While specific formal programs dedicated solely to ensuring alignment are not extensively detailed, the integration of ESG principles into their corporate strategy suggests a structured approach. Their 2024 ESG report highlights their commitment to sustainability and social responsibility.